Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 2/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.41 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.37 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4165826 | 0.88 | HPGD (0.43) | GPR17FFAR1S1PR1HPGDCYP2C19 | |
| SCHEMBL4153837 | 0.87 | GPR17 (0.45) | GPR17FFAR1HPGDCYP2C19PTGER1 | |
| SCHEMBL4163244 | 0.87 | S1PR1 (0.42) | GPR17FFAR1S1PR1HPGDCYP2C19 | |
| SCHEMBL4157488 | 0.82 | MCL1 (0.42) | — | |
| SCHEMBL3245633 | 0.82 | PRKAB2 (0.46) | PAK1PTGESTNKS2CYP2C9PRKAG1 | |
| SCHEMBL4162604 | 0.82 | S1PR1 (0.42) | GPR17S1PR1HPGDCYP2C19CYP2C9 | |
| SCHEMBL4166164 | 0.82 | GPR17 (0.40) | GPR17S1PR1HPGDCYP2C19PTGER1 | |
| SCHEMBL4162598 | 0.81 | HPGD (0.52) | GPR17S1PR1HPGDCYP2C19 | |
| SCHEMBL4164405 | 0.81 | GPR17 (0.40) | GPR17FFAR1S1PR1HPGDCYP2C19 | |
| SCHEMBL4157563 | 0.81 | HPGD (0.49) | GPR17S1PR1HPGDCYP2C19PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | claimed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | claimed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | GPR17 2461/4885FFAR1 3984/4885S1PR1 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.